KorMedi
  • Beauty
  • Health
  • Lifestyle
  • Medicine
  • Biowatch
  • Column
  • Kormedi.com TV
  • Notice
KorMedi
Beauty
Health
Lifestyle
Medicine
Biowatch
Column
Kormedi.com TV
Notice

Search results for "Claudin18.2"

Home
ABL Bio’s Stomach Cancer Drug Shows Promise in Once 'Untreatable' Patients

ABL Bio’s Stomach Cancer Drug Shows Promise in Once 'Untreatable' Patients

South Korean platform biotech company ABL Bio announced that development remains firmly on track despite investor concerns over Sanofi’s recent...
07/12/2026, 06:48 ET
Abl Bio Confirms Positive Effects of Cancer Drug 'ABL111' in Phase 1b Clinical Trial

Abl Bio Confirms Positive Effects of Cancer Drug 'ABL111' in Phase 1b Clinical Trial

Abl Bio announced on the 7th that it has confirmed positive anti-cancer efficacy in the dose expansion cohort of the Phase 1b clinical trial for its...
01/06/2026, 16:01 ET
1
KorMedi
  • Business registration number: 214-87-97051
  • Press registration number: Seoul A 00292
  • Registration date: 2006-11-30
  • Title: Kormedi.com
  • Representative number: 02-2052-8200
  • Address: 41, Mapo-daero 4da-gil, Mapo-gu, Seoul, Henkel Tower (2nd Floor, Mapo Tower)
  • Issue date: November 30, 2006
  • Publisher and Editor-in-Chief: Seong Ju Lee
  • Youth Protection Officer: Simon Hong
  • Company Introduction
  • Privacy Policy
  • Terms of Service
  • Youth Protection Policy
  • Email Collection Refusal
  • Advisory Board
  • Advertising and Partnership Inquiries

Kormedi.com does not provide medical advice, diagnosis or treatment.

Multilingual content on this site is generated using AI-based translation and may contain errors or differences in interpretation. For legal or medical matters, please refer to the original language version.

© 2026 KoreaMedicare. All Rights Reserved.Powered by 팡고링고
Languages

ENGLISH

English (US)

ASIAN

Монгол日本語Tiếng ViệtBahasa Indonesia中文 (简体, 中国大陆)

EUROPEAN

РусскийEspañol (España)Français (France)

MIDDLE_EAST_AFRICA

العربية